A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.

Jesse C NussbaumAzher HussainAnthony FordPeter ButeraMichael KittSteve SmithAubrey StochMarian Iwamoto

Published in: Lung (2022)

The safety profile of gefapixant 300-600 mg BID was generally consistent with previous studies. Additional characterization of gefapixant PK as a function of age and sex using population PK modeling is warranted.

Keyphrases

double blind
physical activity
open label
gestational age
case control